{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:44:39Z","timestamp":1788201879351,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Research Fund of the University of Istanbul","award":["35138"],"award-info":[{"award-number":["35138"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10096-024-05017-0","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T23:26:03Z","timestamp":1734650763000},"page":"587-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The in vitro synergistic and antibiofilm activity of Ceftazidime\/avibactam against Achromobacter species recovered from respiratory samples of cystic fibrosis patients"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4428-5066","authenticated-orcid":false,"given":"Emel","family":"Matarac\u0131-Kara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3168","authenticated-orcid":false,"given":"Damla","family":"Damar-\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-8398","authenticated-orcid":false,"given":"Berna","family":"\u00d6zbek-\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"5017_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/phar.2447","volume":"40","author":"HK Spencer","year":"2020","unstructured":"Spencer HK, Spitznogle SL, Borjan J, Aitken SL (2020) An overview of the treatment of less common non-lactose-fermenting gram-negative bacteria. Pharmacotherapy 40:936\u2013951. https:\/\/doi.org\/10.1002\/phar.2447","journal-title":"Pharmacotherapy"},{"key":"5017_CR2","doi-asserted-by":"publisher","first-page":"e01025","DOI":"10.1128\/AAC.01025-20","volume":"64","author":"B Isler","year":"2020","unstructured":"Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL (2020) Achromobacter infections and treatment options. Antimicrob Agents Chemother 64:e01025-e1120. https:\/\/doi.org\/10.1128\/AAC.01025-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.transproceed.2022.02.032","volume":"54","author":"A Pi\u00f3ro","year":"2022","unstructured":"Pi\u00f3ro A, Latos M, Urlik M, St\u0105cel T, Zawadzki F, Gaw\u0119da M, Pandel A, Przyby\u0142owski P, Knapik P, Ochman M (2022) Various aspects of bacterial infections in the early postoperative stage among lung transplant recipients on broad-spectrum antibiotics: a single center study. Transplant Proc 54:1097\u20131103. https:\/\/doi.org\/10.1016\/j.transproceed.2022.02.032","journal-title":"Transplant Proc"},{"key":"5017_CR4","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.2147\/IDR.S301153","volume":"14","author":"J Vazirani","year":"2021","unstructured":"Vazirani J, Crowhurst T, Morrissey CO, Snell GI (2021) Management of multidrug resistant infections in lung transplant recipients with cystic fibrosis. Infect Drug Resist 14:5293\u20135301. https:\/\/doi.org\/10.2147\/IDR.S301153","journal-title":"Infect Drug Resist"},{"key":"5017_CR5","doi-asserted-by":"publisher","first-page":"e00379","DOI":"10.1128\/aac.00379-23","volume":"67","author":"M Olbrecht","year":"2023","unstructured":"Olbrecht M, Echahidi F, Pi\u00e9rard D, Peeters C, Vandamme P, Wybo I, Demuyser T (2023) In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey. Antimicrob Agents Chemother 67:e00379-e423. https:\/\/doi.org\/10.1128\/aac.00379-23","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5017_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/1120009X.2020.1819702","volume":"33","author":"D Damar-Celik","year":"2021","unstructured":"Damar-Celik D, Matarac\u0131-Kara E, Savage PB, \u00d6zbek-\u00c7elik B (2021) Antibacterial and antibiofilm activities of ceragenins against Achromobacter species isolated from cystic fibrosis patients. J Chemother 33(4):216\u2013227. https:\/\/doi.org\/10.1080\/1120009X.2020.1819702","journal-title":"J Chemother"},{"key":"5017_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jcf","volume":"17","author":"TJ Kidd","year":"2018","unstructured":"Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ (2018) Antimicrobial resistance in cystic fibrosis international working group. Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros 17:696\u2013704. https:\/\/doi.org\/10.1016\/j.jcf","journal-title":"J Cyst Fibros"},{"key":"5017_CR8","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1128\/JCM.39.11.3942-3945.2001","volume":"39","author":"L Saiman","year":"2001","unstructured":"Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z et al (2001) Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 39:3942\u20135. https:\/\/doi.org\/10.1128\/JCM.39.11.3942-3945.2001","journal-title":"J Clin Microbiol"},{"issue":"10","key":"5017_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3109\/00365548.2012.664780","volume":"44","author":"S Atalay","year":"2012","unstructured":"Atalay S, Ece G, Samlio\u011flu P, Kose S, Maras G, Gonullu M (2012) Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans. Scand J Infect Dis 44(10):798\u2013801. https:\/\/doi.org\/10.3109\/00365548.2012.664780","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"5017_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/1120009X.2023.2213600","volume":"35","author":"B \u00d6zer","year":"2023","unstructured":"\u00d6zer B, \u00d6zbek\u00c7el\u0131k B (2023) Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis. J Chemother 35(8):700\u2013706. https:\/\/doi.org\/10.1080\/1120009X.2023.2213600","journal-title":"J Chemother"},{"issue":"1","key":"5017_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","volume":"6","author":"FD Baets","year":"2007","unstructured":"Baets FD, Schelstraete P, Daele SV et al (2007) Achromobacter xylosoxidans infection in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 6(1):75\u201378. https:\/\/doi.org\/10.1016\/j.jcf.2006.05.011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"5017_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/cmr.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25(3):450\u2013470. https:\/\/doi.org\/10.1128\/cmr.05041-11","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"5017_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(08)70279-2","volume":"8","author":"D Karageorgopoulos","year":"2008","unstructured":"Karageorgopoulos D, Falagas ME (2008) Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8(12):751\u2013762. https:\/\/doi.org\/10.1016\/S1473-3099(08)70279-2","journal-title":"Lancet Infect Dis"},{"key":"5017_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jgar.2019.01.004","volume":"17","author":"KZ Vardakas","year":"2019","unstructured":"Vardakas KZ, Athanassaki F, Pitiriga V et al (2019) Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant gram-negative infections: a systematic review. J Glob Antimicrob Resist 17:250\u2013259. https:\/\/doi.org\/10.1016\/j.jgar.2019.01.004","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"5017_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/clinids\/4.2.294","volume":"4","author":"J Klastersky","year":"1982","unstructured":"Klastersky J, Zinner ZS (1982) Synergistic combinations of antibiotics in gram-negative bacillary \u0131nfections. Rev Infect Dis 4(2):294\u2013301. https:\/\/doi.org\/10.1093\/clinids\/4.2.294","journal-title":"Rev Infect Dis"},{"key":"5017_CR16","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1128\/jcm.05283-11","volume":"49","author":"RHV Pereira","year":"2011","unstructured":"Pereira RHV, Carvalho-Assef AP, Albano RM et al (2011) Achromobacter xylosoxidans: characterisation of strains in Brazilian cystic fibrosis patients. J Clin Microbiol 49:3649\u20133651. https:\/\/doi.org\/10.1128\/jcm.05283-11","journal-title":"J Clin Microbiol"},{"key":"5017_CR17","doi-asserted-by":"publisher","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","volume":"62","author":"A Van Dalem","year":"2018","unstructured":"Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, de Wachter E, Vandamme P, Pi\u00e9rard D (2018) In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother 62:e00590-e618. https:\/\/doi.org\/10.1128\/AAC.00590-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR18","doi-asserted-by":"publisher","first-page":"e02688","DOI":"10.1128\/AAC.02688-16","volume":"61","author":"P Grohs","year":"2017","unstructured":"Grohs P, Taieb G, Morand P, Kaibi I, Podglajen I, Lavollay M, Mainardi JL, Compain F (2017) In vitro activity of ceftolozane-tazobactam against multi drug resistant non fermenting Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 61:e02688-e2716. https:\/\/doi.org\/10.1128\/AAC.02688-16","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR19","doi-asserted-by":"publisher","first-page":"e02291","DOI":"10.1128\/AAC.02291-19","volume":"64","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, Melvin SM, Steed ME, Finch NA, Morrisette T, Estrada SJ, Rosenberg JR, Davis SL, Rybak MJ (2020) Real-world experience with ceftolozane-tazobactam for multi drug-resistant Gram-negative bacterial infections. Antimicrob Agents Chemother 64:e02291-e2319. https:\/\/doi.org\/10.1128\/AAC.02291-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CE.S40698","volume":"9","author":"P Lagac\u00e9-Wiens","year":"2014","unstructured":"Lagac\u00e9-Wiens P, Walkty A, Karlowsky JA (2014) Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9:13\u201325. https:\/\/doi.org\/10.2147\/CE.S40698","journal-title":"Core Evid"},{"key":"5017_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrmicro2182","volume":"7","author":"M Otto","year":"2009","unstructured":"Otto M (2009) Staphylococcus epidermidis - the \u201caccidental\u201d pathogen. Nat Rev Microbiol 7:555\u2013567. https:\/\/doi.org\/10.1038\/nrmicro2182","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"5017_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc.15.7","volume":"7","author":"N Rabin","year":"2015","unstructured":"Rabin N, Zheng Y, Opoku-Temeng C, Du YX, Bonsu E, Sintim HO (2015) Agents that inhibit bacterial biofilm formation. Future Med Chem 7(5):647\u2013671. https:\/\/doi.org\/10.4155\/fmc.15.7","journal-title":"Future Med Chem"},{"key":"5017_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fmicb.2016.00330","volume":"7","author":"B Jamil","year":"2016","unstructured":"Jamil B, Habib H, Abbasi SA, Ihsan A, Nasir H, Imran M (2016) Development of cefotaxime impregnated chitosan as nano-antibiotics: De novo strategy to combat biofilm forming multi-drug resistant pathogens. Front Microbiol 7:330. https:\/\/doi.org\/10.3389\/fmicb.2016.00330","journal-title":"Front Microbiol"},{"key":"5017_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.micpath.2018.03.024","volume":"118","author":"JS Novais","year":"2018","unstructured":"Novais JS et al (2018) Antibacterial naphthoquinone derivatives targeting resistant strain Gram-negative bacteria in biofilms. Microb Pathogenesis 118:105\u2013114. https:\/\/doi.org\/10.1016\/j.micpath.2018.03.024","journal-title":"Microb Pathogenesis"},{"key":"5017_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1099\/jmm.0.000499","volume":"66","author":"SS Gade","year":"2017","unstructured":"Gade SS, N\u00f8rskov-Lauritsen N, Ridderberg W (2017) Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the aarhus Centre in Denmark. J Med Microbiol 66:686\u2013689. https:\/\/doi.org\/10.1099\/jmm.0.000499","journal-title":"J Med Microbiol"},{"key":"5017_CR26","unstructured":"CLSI (2022) Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute"},{"key":"5017_CR27","volume-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"1999","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS) (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne PA"},{"issue":"2","key":"5017_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","volume":"40","author":"S Stepanovic","year":"2000","unstructured":"Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40(2):175\u2013179. https:\/\/doi.org\/10.1016\/S0167-7012(00)00122-6","journal-title":"J Microbiol Methods"},{"issue":"1","key":"5017_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.micro.54.1.49","volume":"54","author":"G O\u2019Toole","year":"2000","unstructured":"O\u2019Toole G, Kaplan HB, Kolter R (2000) Biofilm formation as microbial development. Annu Rev Microbiol 54(1):49\u201379. https:\/\/doi.org\/10.1146\/annurev.micro.54.1.49","journal-title":"Annu Rev Microbiol"},{"key":"5017_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/ddr.21893","volume":"83","author":"E Matarac\u0131-Kara","year":"2022","unstructured":"Matarac\u0131-Kara E, Bayrak N, Y\u0131ld\u0131z M, Y\u0131ld\u0131r\u0131m H, \u00d6zbek-\u00c7elik B, Tuyun AF (2022) Discovery and structure\u2013activity relationships of the quinolinequinones: Promising antimicrobial agents and mode of action evaluation. Drug Dev Res 83:628\u2013636. https:\/\/doi.org\/10.1002\/ddr.21893","journal-title":"Drug Dev Res"},{"key":"5017_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1179\/1973947813Y.0000000145","volume":"26","author":"RK Flamm","year":"2014","unstructured":"Flamm RK, Stone GG, Sader HS et al (2014) Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 26:333\u2013338. https:\/\/doi.org\/10.1179\/1973947813Y.0000000145","journal-title":"J Chemother"},{"key":"5017_CR32","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1128\/aac.04191-14","volume":"59","author":"H Li","year":"2015","unstructured":"Li H, Estabrook M, Jacoby GA et al (2015) In vitro susceptibility of characterized b-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59:1789\u201393. https:\/\/doi.org\/10.1128\/aac.04191-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5017_CR33","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3201\/eid2208.151423","volume":"22","author":"S Haviari","year":"2016","unstructured":"Haviari S, Cassier P, Dananch C et al (2016) The outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections after prostate biopsies, France, 2014. Emerg Infect Dis 22(8):1412\u20131419. https:\/\/doi.org\/10.3201\/eid2208.151423","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"5017_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1513\/AnnalsATS.201406-288FR","volume":"12","author":"CE Swenson","year":"2015","unstructured":"Swenson CE, Sadikot RT (2015) Achromobacter respiratory infections. Ann Am Thorac Soc 12(2):252\u2013258. https:\/\/doi.org\/10.1513\/AnnalsATS.201406-288FR","journal-title":"Ann Am Thorac Soc"},{"key":"5017_CR35","doi-asserted-by":"publisher","first-page":"e01595","DOI":"10.1128\/AAC.01595-19","volume":"64","author":"LJ Caverly","year":"2020","unstructured":"Caverly LJ, Spilker T, Kalikin LM, Stillwell T, Young C, Huang DB, LiPuma JJ (2020) In vitro activities of \u03b2-lactam\u2013\u03b2-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens. Antimicrob Agents Chemother 64:e01595-e1619. https:\/\/doi.org\/10.1128\/AAC.01595-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5017_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0034-1396929","volume":"36","author":"IJ Abbott","year":"2015","unstructured":"Abbott IJ, Peleg AY (2015) Stenotrophomonas, achromobacter, and nonmelioid burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med 36(1):99\u2013110. https:\/\/doi.org\/10.1055\/s-0034-1396929","journal-title":"Semin Respir Crit Care Med"},{"key":"5017_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijantimicag.2009.08.015","volume":"35","author":"M Almuzara","year":"2010","unstructured":"Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C (2010) In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int J Antimicrob Agents 35:68\u201371. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.08.015","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"5017_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1099\/jmm.0.000801","volume":"67","author":"V Mathy","year":"2018","unstructured":"Mathy V, Grohs P, Compain F (2018) In vitro activity of \u03b2-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. J Med Microbiol 67(9):1217\u20131220. https:\/\/doi.org\/10.1099\/jmm.0.000801","journal-title":"J Med Microbiol"},{"issue":"4","key":"5017_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jhin.2015.02.005","volume":"89","author":"K Schaffer","year":"2015","unstructured":"Schaffer K (2015) Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect 89(4):309\u2013313. https:\/\/doi.org\/10.1016\/j.jhin.2015.02.005","journal-title":"J Hosp Infect"},{"issue":"6","key":"5017_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00284-012-0213-5","volume":"65","author":"GM Traglia","year":"2012","unstructured":"Traglia GM, Almuzara M, Merkier AK et al (2012) Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol 65(6):673\u2013678. https:\/\/doi.org\/10.1007\/s00284-012-0213-5","journal-title":"Curr Microbiol"},{"issue":"6","key":"5017_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/AAC.01463-07","volume":"52","author":"Y Doi","year":"2008","unstructured":"Doi Y, Poirel L, Paterson DL, Nordmann P (2008) Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. Antimicrob Agents Chemother 52(6):1952\u20136. https:\/\/doi.org\/10.1128\/AAC.01463-07","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jgar.2020.06.001","volume":"22","author":"D Damar-\u00c7elik","year":"2020","unstructured":"Damar-\u00c7elik D, N\u00f8rskov-Lauritsen N, \u00d6zbek-\u00c7elik B (2020) Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis. J Global Antimicrob Resist 22:713\u2013717. https:\/\/doi.org\/10.1016\/j.jgar.2020.06.001","journal-title":"J Global Antimicrob Resist"},{"key":"5017_CR43","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.52586\/5054","volume":"26","author":"S Esposito","year":"2021","unstructured":"Esposito S, Pisi G, Fainardi V, Principi N (2021) What is the role of Achromobacter species in patients with cystic fibrosis? Front Biosci (Landmark Ed) 26:1613\u20131620. https:\/\/doi.org\/10.52586\/5054","journal-title":"Front Biosci (Landmark Ed)"},{"key":"5017_CR44","doi-asserted-by":"publisher","first-page":"e0092021","DOI":"10.1128\/AAC.00920-21","volume":"65","author":"N Somprasong","year":"2021","unstructured":"Somprasong N, Yi J, Hall CM, Webb JR, Sahl JW, Wagner DM, Keim P, Currie BJ, Schweizer HP (2021) Conservation of resistance-nodulation-cell division efflux pump-mediated antibiotic resistance in Burkholderia cepacia complex and Burkholderia pseudomallei complex species. Antimicrob Agents Chemother 65:e0092021. https:\/\/doi.org\/10.1128\/AAC.00920-21","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR45","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1513\/AnnalsATS.201701-071OC","volume":"14","author":"R Somayaji","year":"2017","unstructured":"Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V (2017) Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis. Ann Am Thorac Soc 14:1412\u20131418. https:\/\/doi.org\/10.1513\/AnnalsATS.201701-071OC","journal-title":"Ann Am Thorac Soc"},{"key":"5017_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jcf.2012.08.005","volume":"12","author":"L Amoureux","year":"2013","unstructured":"Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C (2013) Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros 12:170\u2013176. https:\/\/doi.org\/10.1016\/j.jcf.2012.08.005","journal-title":"J Cyst Fibros"},{"key":"5017_CR47","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1128\/AAC.40.6.1412","volume":"40","author":"RJ Fass","year":"1996","unstructured":"Fass RJ, Barnishan J, Solomon MC, Ayers LW (1996) In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 40:1412\u20131418. https:\/\/doi.org\/10.1128\/AAC.40.6.1412","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5017_CR48","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/23744235.2020.1767803","volume":"52","author":"E Mataraci Kara","year":"2020","unstructured":"Mataraci Kara E, Yilmaz M, \u0130stanbulluTosun A, \u00d6zbek\u00c7elik B (2020) Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa. Infect Dis (Lond) 52(9):616\u2013624. https:\/\/doi.org\/10.1080\/23744235.2020.1767803","journal-title":"Infect Dis (Lond)"},{"key":"5017_CR49","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jac\/dku530","volume":"70","author":"N Eliakim-Raz","year":"2015","unstructured":"Eliakim-Raz N, Lador A, Leibovici-Weissman Y, Elbaz M, Paul M, Leibovici L (2015) Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 70:979\u2013996. https:\/\/doi.org\/10.1093\/jac\/dku530","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"5017_CR50","first-page":"371","volume":"12","author":"O Nitzan","year":"2010","unstructured":"Nitzan O, Suponitzky U, Kennes Y, Chazan B, Raul R, Colodner R (2010) Is chloramphenicol making a comeback? Isr Med Assoc J 12(6):371\u2013374","journal-title":"Isr Med Assoc J"},{"key":"5017_CR51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","volume":"11","author":"G D\u00f6ring","year":"2012","unstructured":"D\u00f6ring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group (2012) Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11:461\u201379. https:\/\/doi.org\/10.1016\/j.jcf.2012.10.004","journal-title":"J Cyst Fibros"},{"key":"5017_CR52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","volume":"168","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918\u2013951. https:\/\/doi.org\/10.1164\/rccm.200304-505SO","journal-title":"Am J Respir Crit Care Med"},{"key":"5017_CR53","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000321015","volume":"56","author":"B Ozbek","year":"2010","unstructured":"Ozbek B, \u015eent\u00fcrk A (2010) Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy 56:466\u2013471. https:\/\/doi.org\/10.1159\/000321015","journal-title":"Chemotherapy"},{"key":"5017_CR54","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/jac\/dku065","volume":"69","author":"P Gaibani","year":"2014","unstructured":"Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP et al (2014) In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 69:1856\u20131865. https:\/\/doi.org\/10.1093\/jac\/dku065","journal-title":"J Antimicrob Chemother"},{"key":"5017_CR55","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1128\/AAC.00065-10","volume":"54","author":"A Louie","year":"2010","unstructured":"Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R (2010) The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 54:2646\u20132654. https:\/\/doi.org\/10.1128\/AAC.00065-10","journal-title":"Antimicrob Agents Chemother"},{"key":"5017_CR56","doi-asserted-by":"publisher","first-page":"566325","DOI":"10.3389\/fmicb.2020.566325","volume":"11","author":"R Mishra","year":"2020","unstructured":"Mishra R, Panda AK, De Mandal S, Shakeel M, Bisht SS, Khan J (2020) Natural anti-biofilm agents: strategies to control biofilm-forming pathogens. Front Microbiol 11:566325. https:\/\/doi.org\/10.3389\/fmicb.2020.566325","journal-title":"Front Microbiol"},{"issue":"1","key":"5017_CR57","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/21505594.2017.1313372","volume":"9","author":"R Roy","year":"2018","unstructured":"Roy R, Tiwari M, Donelli G, Tiwari V (2018) Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence 9(1):522\u2013554. https:\/\/doi.org\/10.1080\/21505594.2017.1313372","journal-title":"Virulence"},{"key":"5017_CR58","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511525353","volume-title":"Microbial biofilms","author":"HM Lappin-Scott","year":"1995","unstructured":"Lappin-Scott HM, Costerton JW (1995) Microbial biofilms. Cambridge University Pres"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-05017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-05017-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-05017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:23:22Z","timestamp":1741098202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-05017-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["5017"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-05017-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Eth\u0131cal approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}